Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 104 clinical trials
featured
A PHASE 3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

For patients with autosomal dominant polycystic kidney disease (ADPKD) enrolled in this study, the objectives to assess bardoxolone methyl relative to placebo are as follows:

  • 63 views
  • 23 Nov, 2020
  • 2 locations
featured
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Disease

A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Disease

  • 184 views
  • 23 Nov, 2020
  • 1 location
featured
Autosomal Dominant Polycystic Kidney Disease Registry. Male/female 18 years of age or older, diagnosed with ADPKD.

Autosomal Dominant Polycystic Kidney Disease Registry. Male/female 18 years of age or older, diagnosed with ADPKD.

  • 170 views
  • 08 Nov, 2020
  • 1 location
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: To determine the effect of venglustat on the rate

chronic kidney disease
renal disease
renal function
human chorionic gonadotropin
glomerular filtration rate
  • 82 views
  • 26 Jan, 2021
  • 127 locations
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease

autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese. The study will provide valuable information on the intervention in terms of safety, adherence, acceptability, and

  • 0 views
  • 26 Jan, 2021
  • 1 location
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy in subjects who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible subjects will be enrolled and treated …

chronic kidney disease
renal disease
body mass index
hypertension
tolvaptan
  • 0 views
  • 26 Jan, 2021
  • 4 locations
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

Primary Objective To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine To assess the safety and tolerability of RGLS4326

  • 0 views
  • 27 Jan, 2021
  • 7 locations
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD). This study examines the

hypertension
renal disease
cilnidipine
  • 26 views
  • 07 Nov, 2020
  • 7 locations
Effect of Rapeseed Oil and Sunflower Oil

Familial hypercholesterolemia (FH), an inherited disorder of lipoprotein metabolism, is a risk for early cardiovascular disease (CVD). This autosomal dominant disease is characterized by

LDL Cholesterol
low density lipoprotein
sunflower oil
autosomal dominant
cardiovascular disease
  • 23 views
  • 07 Nov, 2020
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

is that treatment with HCQ is safe and tolerable in patients with autosomal dominant retinitis pigmentosa (adRP) caused by P23H-RHO, and may arrest progression of retinal degeneration by altering the

genetic testing
genetic analysis
retinal degeneration
antacids
retinopathy
  • 45 views
  • 23 Jan, 2021
  • 1 location